Ynios Pharma

TLDR

YNIOS Pharma is a biotech company developing TA64, a therapeutic compound targeting sepsis, septic shock, and other critical care conditions through regulated inflammation and immune dysfunction mechanisms.

Overview

YNIOS PHARMA is a biotechnology company developing an innovative therapeutic platform for patients with life-threatening critical illnesses, starting with sepsis and septic shock. The lead compound TA64 targets pathophysiological mechanisms including unregulated inflammation, endothelial dysfunction, microcirculatory failure, and immune exhaustion. Beyond septic shock, the platform aims to extend to other critical care conditions sharing similar biological pathways, such as acute respiratory distress syndrome, systemic inflammatory states, and critical conditions related to trauma or burns.